IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3362
Positioning
Market Dominance
Manufacturing
Automobiles And Trucks
$346M
Thomas J. Healy
Hyliion Holdings Corp. designs, develops, and sells electrified powertrain solutions for the commercial vehicle industry. The company also provides battery management systems for hybrid and fully electric vehicle applications.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$HYLN Hyliion Holdings Corp. | 41 | 35 | 46 | 52 | - | - | -27.1% | -25.5% | 1.6% | -2359.9% | -2057.0% | -8.7% | 0.0% | 6.0x | $346M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Hyliion Holdings Corp. (HYLN) receives a "Reduce" rating with a composite score of 41.4/100. It ranks #3362 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Thomas J. Healy
Chief Executive Officer
Labor Force
250
35
33
35
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for HYLN
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for HYLN.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -27.1% (sector -2.5%)
GM 2% vs sector 43%, OM -2360% vs sector 1%
Capital turnover N/A, R&D intensity 1176.4%
Rev growth -9%, 6yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Hyliion Holdings Corp. receives a Reduce rating from our analysis, with a composite score of 41.4/100 and 2 out of 5 stars, ranking #3362 out of 7,333 stocks. HYLN's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
HYLN's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -27.1% (sector avg: -2.5%), gross margins of 1.6% (sector avg: 42.5%), net margins of -2057.0% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 46/100, HYLN appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 1.74x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Hyliion Holdings Corp.'s investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -8.7% vs. a sector average of 5.9% and a return on assets of -25.5% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
HYLN demonstrates moderate momentum with a score of 52/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -8.7% year-over-year, while a beta of 1.65 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
HYLN's stability score of 35/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.65 and a debt-to-equity ratio of 6.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Hyliion Holdings Corp.'s short interest score of 35/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.65), elevated leverage (D/E: 6.00x), small-cap liquidity risk. At $346M (small-cap), HYLN carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Hyliion Holdings Corp. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3362 of 7,333 overall (54th percentile). Key comparisons include ROE of -27.1% trailing the -2.5% sector median and operating margins of -2359.9% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While HYLN currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (33) would have the largest impact on the composite score.
ROE 992% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 96% BELOW SECTOR MEDIAN
Op. Margin 183040% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Hyliion Holdings Corp. (HYLN) as a Reduce with a composite score of 41.4/100 at a current price of $2.00. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (52th percentile) and value (46th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (33th percentile) and stability (35th percentile) tempers our overall conviction. We assign a No Moat rating (24/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Hyliion Holdings Corp. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.4/100 places it at rank #3362 in our full 7,333-stock universe. At $346M in market capitalization, Hyliion Holdings Corp. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -9% combined with momentum at the 52th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 2% (-40.9pp vs sector) narrow to operating margins of -2360% (-2361.2pp vs sector) and net margins of -2057.0%, yielding a gross-to-net conversion rate of -125683%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $2.00, Hyliion Holdings Corp. is trading near fair value based on current fundamentals. Our value factor score of 46/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 1.7x, P/S of 128.0x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (6% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Reduce rating (composite 41.4/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -9% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -2057.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
High beta of 1.65 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
We assign a High uncertainty rating to Hyliion Holdings Corp.. Key risk factors include elevated market sensitivity (beta of 1.65), current negative profitability (net margin -2057.0%), below-average price stability (35th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.65); current negative profitability (net margin -2057.0%); below-average price stability (35th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 35th percentile and quality factor at the 35th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (6% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Hyliion Holdings Corp.'s capital allocation as Poor. Key concerns include low returns on equity (-27.1%), negative profitability, weak asset returns (ROA -25.5%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Hyliion Holdings Corp. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Hyliion Holdings Corp. receives a Reduce rating with a composite score of 41.4/100 (rank #3362 of 7,333). Our quantitative framework assigns a No Moat (24/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 40/100.
Our analysis does not support a constructive view on Hyliion Holdings Corp. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Hyliion Holdings Corp. a meaningful economic moat, scoring 24/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, financial resilience, reached only 9.3/20.
The strongest moat sources are financial resilience (9.3/20) and reinvestment efficiency (7/20). Interest coverage N/A. Capital turnover N/A, R&D intensity 1176.4%. These pillars form the core of Hyliion Holdings Corp.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include margin superiority (0.3/20) and economic value creation (2.7/20). GM 2% vs sector 43%, OM -2360% vs sector 1%. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Hyliion Holdings Corp.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-9%) that pressure the earnings outlook. The margin cascade from 2% gross to -2360% operating to -2057.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 35th percentile.
The margin profile shows gross margins of 2%, operating margins of -2360%, net margins of -2057.0%. Return metrics include ROE of -27.1% and ROA of -25.5%. Relative to the Manufacturing sector, gross margins are 40.9 percentage points below the sector median of 43%, and ROE of -27.1% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 6%, revenue growth of -9%. The sector median D/E is 0%, putting Hyliion Holdings Corp. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Upgrades According to Craig-Hallum, the prior rating for MasTec Inc (NYSE:MTZ) was changed from Hold to Buy. In the second quarter, MasTec showed an EPS of $0.89, compared to $0.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $123.33 and a 52-week-low of $62.44. MasTec closed at $67.02 at the end of the last trading period. According to Janney Montgomery Scott, the prior rating for Central Valley Community Bancorp (NASDAQ:CVCY) was changed from Neutral to Buy. In the second quarter, Central Valley Community showed an EPS of $0.54, compared to $0.56 from the year-ago quarter. The current stock performance of Central Valley Community shows a 52-week-high of $25.99 and a 52-week-low of $12.59. Moreover, at the end of the last trading period, the closing price was at $15.34. B of A Securities upgraded the previous rating for Target Corp (NYSE:TGT) from Neutral to Buy. Target earned $1.80 in the second quarter, compared to $0.39 in the year-ago quarter. The current stock performance of Target shows a 52-week-high of $181.70 and a 52-week-low of $102.93. Moreover, at the end of the last trading period, the closing price was at $108.99. For Exxon Mobil Corp (NYSE:XOM), Truist Securities upgraded the previous rating of Hold to Buy. Exxon Mobil earned $1.94 in the second quarter, compared to $4.14 in the year-ago quarter. The stock has a 52-week-high of $120.70 and a 52-week-low of $96.76. At the end of the last trading period, Exxon Mobil closed at $106.49. According to BTIG, the prior rating for Warby Parker Inc (NYSE:WRBY) was changed from Neutral to Buy. Warby Parker earned $0.04 in the second quarter, compared to $0.01 in the year-ago quarter. The stock has a 52-week-high of $18.97 and a 52-week-low of $9.50. At the end of the last trading period, Warby Parker closed at $14.21. JP Morgan upgraded the previous rating for Tanger Factory Outlet Centers Inc (NYSE:SKT) from Underweight to Neutral. Tanger Factory Outlet earned $0.47 in the second quarter, compared to $0.45 in the year-ago quarter. The current stock performance of Tanger Factory Outlet shows a 52-week-high of $25.23 and a 52-week-low of $14.85. Moreover, at the end of the last trading period, the closing price was at $23.11. According to JP Morgan, the prior rating for Healthcare Realty Trust Inc (NYSE:HR) was changed from Neutral to Overweight. In the second quarter, Healthcare Realty Trust showed an EPS of $0.39, compared to $0.45 from the year-ago quarter. The stock has a 52-week-high of $22.36 and a 52-week-low of $14.15. At the end of the last trading period, Healthcare Realty Trust closed at $15.07. For Core & Main Inc (NYSE:CNM), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. Core & Main earned $0.66 in the second quarter, compared to $0.67 in the year-ago quarter. The stock has a 52-week-high of $33.32 and a 52-week-low of $18.79. At the end of the last trading period, Core & Main closed at $31.18. For Kimberly-Clark Corp (NYSE:KMB), Bernstein upgraded the previous rating of Underperform to Market Perform. Kimberly-Clark earned $1.65 in the second quarter, compared to $1.34 in the year-ago quarter. The current stock performance of Kimberly-Clark shows a 52-week-high of $147.87 and a 52-week-low of $110.38. Moreover, at the end of the last trading period, the closing price was at $119.35. For Clorox Co (NYSE:CLX), Bernstein upgraded the previous rating of Underperform to Market Perform. In the fourth quarter, Clorox showed an EPS of $1.67, compared to $0.93 from the year-ago quarter. At the moment, the stock has a 52-week-high of $178.21 and a 52-week-low of $119.56. Clorox closed at $122.36 at the end of the last trading period. According to Barclays, the prior rating for First Solar Inc (NASDAQ:FSLR) was changed from Equal-Weight to Overweight. For the second quarter, First Solar had an EPS of $1.89, compared to year-ago quarter EPS of $0.52. The stock has a 52-week-high of $232.00 and a 52-week-low of $115.66. At the end of the last trading period, First Solar closed at $151.50. JP Morgan upgraded the previous rating for Gold Fields Ltd (NYSE:GFI) from Underweight to Neutral. NoneThe stock has a 52-week-high of $17.78 and a 52-week-low of $7.29. At the end of the last trading period, Gold Fields closed at $13.11. According to DA Davidson, the prior rating for Dynatrace Inc (NYSE:DT) was changed from Neutral to Buy. In the first quarter, Dynatrace showed an EPS of $0.27, compared to $0.18 from the year-ago quarter. At the moment, the stock has a 52-week-high of $55.87 and a 52-week-low of $31.55. Dynatrace closed at $48.18 at the end of the last trading period. See all analyst ratings upgrades. Downgrades RBC Capital downgraded the previous rating for ResMed Inc (NYSE:RMD) from Outperform to Sector Perform. ResMed earned $1.60 in the fourth quarter, compared to $1.49 in the year-ago quarter. The stock has a 52-week-high of $243.52 and a 52-week-low of $136.20. At the end of the last trading period, ResMed closed at $144.23. According to Exane BNP Paribas, the prior rating for Carvana Co (NYSE:CVNA) was changed from Outperform to Neutral. In the second quarter, Carvana showed an EPS of $0.55, compared to $2.35 from the year-ago quarter. The stock has a 52-week-high of $57.19 and a 52-week-low of $3.56. At the end of the last trading period, Carvana closed at $37.87. According to Cantor Fitzgerald, the prior rating for Hyliion Holdings Corp (NYSE:HYLN) was changed from Neutral to Underweight. For the second quarter, Hyliion Holdings had an EPS of $0.19, compared ...Full story available on Benzinga.com
Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) jumped 59.5% to $2.17. Phio Pharmaceuticals presented new data for targeting of BRD4 with its INTASYL™ compound PH-894. Tupperware Brands Corporation (NYSE: TUP) surged 42.5% to $2.14. Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR) gained 41.4% to $1.2586 after falling 7% on Tuesday. ReTo Eco-Solutions, Inc. (NASDAQ: RETO) jumped 37.3% to $0.7461. Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares climbed 32.6% to $1.18 after falling over 12% on Tuesday. Gaucho Group announced its journey towards organic cultivation for select sections of its renowned Pinot Noir and Cabernet Sauvignon vineyards. Clearmind Medicine Inc. (NASDAQ: CMND) gained 28.5% to $0.1934. Celularity Inc. (NASDAQ: CELU) rose 26.2% to $0.25. Asset Entities Inc. (NASDAQ: ASST) gained 26% to $0.3870. Asset Entities recently announced it received a notice from the Nasdaq saying that it is not in compliance with the minimum bid price requirement. Mangoceuticals, Inc. (NASDAQ: MGRX) shares climbed 25.3% to $0.7440 after gaining 9% on Tuesday. Sharecare, Inc. (NASDAQ: SHCR) shares surged 22.8% to $1.1494. On Oct. 3, 2023, John Chadwick submitted a preliminary non-binding proposal to the board on behalf of Claritas Capital, related to the proposed acquisition of all of the Sharecare shares not owned by reporting persons for $1.35 to $1.80 per share in cash. TC Biopharm (Holdings) Plc (NASDAQ: TCBP) rose 22.6% to $0.4298. voxeljet AG (NASDAQ: VJET) gained 22.3% to $1.26 after the company announced it was selected for a $14.9 million contract alongside GE Research to develop advanced manufacturing technologies to enable the U.S. energy transition. VOXX International Corp (NASDAQ: VOXX) shares jumped 22% to $9.51 as the company reported stronger-than-expected sales for its second quarter. Baudax Bio, Inc. (NASDAQ: BXRX) gained 21.7% to $0.3188. Origin Materials, Inc. (NASDAQ: ORGN) jumped 20.3% to $1.1650. Origin Materials announced commencement of commercial-scale production at Origin 1. AgileThought, Inc. (NASDAQ: AGIL) rose 20% to $0.1775. On Oct. 10, 2023, The Bankruptcy Court entered an order approving AgileThought Parties' and stalking horse buyer's entry into agreement. Ontrak, Inc. (NASDAQ: OTRK) gained 18.1% to $0.8380. Golden Heaven Group Holdings Ltd. (NASDAQ: GDHG) gained 16% to $9.25. Atreca, Inc. (NASDAQ: BCEL) shares ...
As of Dec. 21, 2023, five stocks in the industrials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. Innovative Solutions and Support, Inc. (NASDAQ: ISSC) On Dec. 20, the company posted better-than-expected quarterly results. Shahram Askarpour, Chief Executive Officer of IS&S, said, "I am pleased to report our fifth consecutive year of both top and bottom-line growth as a result of one of the best quarters in the Company’s recent history. The results include some customer-directed accelerated shipments of the acquired Honeywell products to mitigate any impacts from ...
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday. The Dow traded down 0.01% to 33,736.15 while the NASDAQ rose 0.42% to 13,619.46. The S&P 500 also rose, gaining, 0.14% to 4,364.45. Check This Out: Top 5 Consumer Stocks That May Implode This Quarter Leading and Lagging Sectors Real estate shares surged by 1% on Wednesday. In trading on Wednesday, energy shares fell by 1.6%. Top Headline Producer prices in the U.S. increased 0.5% month-over-month in September, versus a 0.7% rise in the prior month, but above market expectations of 0.3%. Equities Trading UP Tempest Therapeutics, Inc. (NASDAQ: TPST) shares shot up 1,713% to $4.35 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study. Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) got a boost, shooting 60% to $2.1695 after the company announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and ...
U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Wednesday. The Dow traded down 0.19% to 33,674.66 while the NASDAQ rose 0.18% to 13,586.67. The S&P 500 also rose, gaining, 0.12% to 4,353.19. Check This Out: Top 5 Consumer Stocks That May Implode This Quarter Leading and Lagging Sectors Real estate shares surged by 0.9% on Wednesday. In trading on Wednesday, energy shares fell by 1.9%. Top Headline Producer prices in the U.S. increased 0.5% month-over-month in September, versus a 0.7% rise in the prior month, but above market expectations of 0.3%. Equities Trading UP Tempest Therapeutics, Inc. (NASDAQ: TPST) shares shot up 1942% to $4.90 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in first-line hepatocellular carcinoma study. Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) got a boost, shooting 59% to $2.16 after the company announced the poster presentation of two key preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...